



Patient Information:
13156, DONOR
DOB: [REDACTED]
Sex: M
MR#: [REDACTED]
Patient#: FT-PT8704376

Partner Information:
Not Tested


Physician:
Kuan, James
ATTN: Kuan, James
Seattle Sperm Bank
4915 25th Avenue NE, Ste 204W
Seattle, WA 98105
Phone: (206) 588-1484

Laboratory:
Fulgent Therapeutics LLC
CAP#: 8042697
CLIA#: 05D2043189
Laboratory Director:
Lawrence M. Weiss, MD
Report Date: **Apr 26, 2024**

Accession:
FT-7062409
Test#: FT-TS14811036
Specimen Type: Blood (EDTA)
Collected: Mar 15, 1990

Accession:
N/A

FINAL RESULTS



TEST PERFORMED

Beacon Preconception Carrier Screening - 515 Genes (without X-linked Disorders)
(515 Gene Panel; gene sequencing with deletion and duplication analysis)

Condition and Gene	Inheritance	13156, DONOR	Partner
Mevalonate kinase deficiency <i>MVK</i>	AR	⊕ Carrier c.1129G>A (p.Val377Ile)	N/A
Methylmalonic aciduria and homocystinuria, cblC type <i>MMACHC</i>	AR	⊕ Carrier c.271dup (p.Arg91Lysfs*14)	N/A

INTERPRETATION:

Notes and Recommendations:

- **PLEASE NOTE: While some heterozygous variants in the MVK gene have been associated with autosomal dominant porokeratosis-3 (POROK3), the reported variant has not been associated with those findings.**
- Based on these results, this individual is positive for carrier mutations in 2 genes. Carrier screening for the reproductive partner is recommended to accurately assess the risk for any autosomal recessive conditions. A negative result reduces, but does not eliminate, the chance to be a carrier for any condition included in this screen. Please see the supplemental table for details.
- Testing for copy number changes in the SMN1 gene was performed to screen for the carrier status of Spinal Muscular Atrophy. The results for this individual are within the normal range for non-carriers. See Limitations section for more information.
- This carrier screening test does not screen for all possible genetic conditions, nor for all possible mutations in every gene tested. This report does not include variants of uncertain significance; only variants classified as pathogenic or likely pathogenic at the time of testing, and considered relevant for reproductive carrier screening, are reported. Please see the gene specific notes for details. Please note that the classification of variants can change over time.
- Patients may wish to discuss any carrier results with blood relatives, as there is an increased chance that they are also carriers. These results should be interpreted in the context of this individual's clinical findings, biochemical profile, and family history.
- X-linked genes are not routinely analyzed for male carrier screening tests. Gene specific notes and limitations may be present. See below.
- Genetic counseling is recommended. Available genetic counselors and additional resources can be found at the National Society of Genetic Counselors (NSGC; <https://www.nsgc.org>).



MEVALONATE KINASE DEFICIENCY

Patient	13156, DONOR	Partner
Result	⊕ Carrier	N/A
Variant Details	MVK (NM_000431.4) c.1129G>A (p.Val377Ile)	N/A

What is Mevalonate kinase deficiency?

There are two types of mevalonate kinase deficiency: a severe type called mevalonic aciduria (MVA) and a less severe type called hyperimmunoglobulinemia D syndrome (HIDS).

- Mevalonic aciduria is characterized by recurrent episodes of inflammation and fever that begin in infancy that typically last from 3 to 6 days. The frequency of these episodes varies from person to person. Children with mevalonate kinase deficiency may have failure to thrive, developmental delay, movement disorders, seizures, vision loss, liver disease, or myopathy. Additionally, patients may have other symptoms of rheumatological disease such as enlarged lymph nodes, abdominal pain, joint pain, diarrhea, skin rashes, headaches, ulcers around the mouth or genitals, or kidney disease.
- Hyperimmunoglobulinemia D syndrome is the less severe form of MVK-related disease. This condition is characterized by recurrent episodes of inflammation and fever that begin in infancy and typically last from 3 to 6 days. The frequency of these episodes vary from person to person. Additionally, patients may have other symptoms of rheumatological disease such as enlarged lymph nodes, abdominal pain, joint pain, diarrhea, skin rashes, headaches, ulcers around the mouth or genitals, or kidney disease.

What is my risk of having an affected child?

If the patient and the partner are both carriers, the risk for an affected child is 1 in 4 (25%).

What kind of medical management is available?


Steroids and other immunosuppressive drugs can be used to treat mevalonate kinase deficiency, however, the response to therapy varies from person to person. Children with severe mevalonic aciduria that is not responsive to medication may require stem cell transplantation. Severely affected individuals may live only into early childhood and have lifelong medical complications. Mildly affected individuals may have a normal life expectancy with treatment.

What mutation was detected?

The detected heterozygous variant was NM_000431.4:c.1129G>A (p.Val377Ile). This variant, p.Val377Ile, has been previously reported as homozygous or compound heterozygous in multiple patients with hyper-IgD syndrome and mevalonate kinase deficiency and has been shown to reduce the activity of the encoded protein (PubMed: [10369261](#), [24360083](#), [26977311](#), [28638818](#), [29290516](#), [26620804](#), [10896296](#), [30783801](#), [35387795](#)). Additionally, this alteration has also been reported as compound heterozygous in two patients with early-onset inflammatory colitis (PubMed: [23979089](#)). This variant is classified as "Pathogenic/Likely pathogenic" in ClinVar, with multiple submitters in agreement (ClinVar: 11929). The laboratory classifies this variant as pathogenic.



METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, CBLC TYPE

Patient	13156, DONOR	Partner
Result	 Carrier	N/A
Variant Details	MMACHC (NM_015506.3) c.271dup (p.Arg91Lysfs*14)	N/A

What is Methylmalonic aciduria and homocystinuria, cblC type?

Methylmalonic aciduria and homocystinuria is a condition in which the body is unable to process certain fats and proteins. When the condition begins early in life, affected individuals typically have failure to thrive, difficulty feeding, and an abnormally pale appearance. Neurological problems are also common in methylmalonic aciduria and homocystinuria, including hypotonia, seizures, microcephaly, delayed development, and intellectual disabilities. The signs and symptoms worsen over time and the condition can be life-threatening if not treated.

What is my risk of having an affected child?

Methylmalonic aciduria and homocystinuria is inherited in an autosomal recessive manner. This means that when both parents are carriers for the same condition, there is a 25% (1 in 4) risk of having an affected child.

What kind of medical management is available?

There is currently no cure for Methylmalonic aciduria and homocystinuria, but the early institution of dietary therapy may reduce but not completely prevent primary symptoms. Avoidance of prolonged fasting and dehydration may reduce episodes of metabolic decompensation. Other options for medical management include the use of certain medications and antibiotics.

What mutation was detected?

The detected heterozygous variant was NM_015506.3:c.271dup (p.Arg91Lysfs*14). This frameshift variant is the result of the duplication of one base pair, which leads to an out-of-frame transcript and the introduction of a premature stop codon. The introduced stop codon is predicted to be located at least 50 nucleotides upstream of the canonical donor splice site of the penultimate exon and is consistent with the resulting transcript being targeted for nonsense mediated decay (PubMed: [25741868](#), [27618451](#), [11532962](#), [18066079](#)). There is sufficient evidence that loss of function in this gene is a known disease mechanism for combined methylmalonic aciduria and homocystinuria of complementation group cblC (PubMed: [19370762](#), [20631720](#), [26287336](#), [28693988](#)). This frameshift variant, known as one of the most frequent mutations observed in the MMACHC gene, has been previously reported in the homozygous and compound heterozygous state in multiple individuals with methylmalonic aciduria cobalamin deficiency type C with homocystinuria. In addition, functional studies in patient fibroblasts demonstrated that the p.Arg91LysfsTer variant results in significantly lower levels of transcript compared to the wild type (PubMed: [16311595](#), [19760748](#), [20631720](#), [21228398](#), [31574870](#), [26990548](#), [16714133](#), [17768669](#), [24599607](#), [25894566](#)). This variant is classified as "Pathogenic" in ClinVar, with multiple clinical laboratory submitters in agreement (ClinVar: 1421). The laboratory classifies this variant as pathogenic.



GENES TESTED:

Beacon Preconception Carrier Screening - 515 Genes (without X-linked Disorders) - 515 Genes

This analysis was run using the Beacon Preconception Carrier Screening - 515 Genes (without X-linked Disorders) gene list. 515 genes were tested with 99.4% of targets sequenced at >20x coverage. For more gene-specific information and assistance with residual risk calculation, see the SUPPLEMENTAL TABLE.

AAAS, ABCA12, ABCA3, ABCA4, ABCB11, ABCB4, ABCC2, ABCC8, ACAD9, ACADM, ACADVL, ACAT1, ACOX1, ACSF3, ADA, ADAMTS2, ADAMTSL4, ADGRG1, ADGRV1, AGA, AGL, AGPS, AGXT, AHI1, AIPL1, AIRE, ALDH3A2, ALDH7A1, ALDOB, ALG1, ALG6, ALMS1, ALPL, AMN, AMT, ANO10, AP1S1, AQP2, ARG1, ARL6, ARSA, ARSB, ASL, ASNS, ASPA, ASS1, ATM, ATP6V1B1, ATP7B, ATP8B1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BCKDHA, BCKDHB, BCS1L, BLM, BLOC1S3, BLOC1S6, BMP1, BRIP1, BSND, CAD, CANT1, CAPN3, CASQ2, CBS, CC2D1A, CC2D2A, CCDC103, CCDC39, CCDC88C, CD3D, CD3E, CD40, CD59, CDH23, CEP152, CEP290, CERKL, CFTR, CHAT, CHRNE, CHRNG, CIITA, CLCN1, CLN3, CLN5, CLN6, CLN8, CLRN1, CNGB3, COL11A2, COL17A1, COL27A1, COL4A3, COL4A4, COL7A1, COX15, CPS1, CPT1A, CPT2, CRB1, CRTAP, CRYL1, CTNS, CTSA, CTSC, CTSD, CTSK, CYBA, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP1B1, CYP21A2, CYP27A1, CYP27B1, CYP7B1, DBT, DCAF17, DCLRE1C, DDX11, DGAT1, DGUOK, DHCR7, DHDDS, DLD, DLL3, DNAH11, DNAH5, DNAI1, DNAI2, DNMT3B, DOK7, DUOX2, DYNC2H1, DYSF, EIF2AK3, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, ELP1, EPG5, ERCC2, ERCC6, ERCC8, ESCO2, ETFA, ETFB, ETFDH, ETHE1, EVC, EVC2, EXOSC3, EYS, FAH, FAM161A, FANCA, FANCC, FANCD2, FANCE, FANCG, FANCI, FANCL, FBP1, FBXO7, FH, FKBP10, FKRP, FKTN, FMO3, FOXN1, FOXRED1, FRAS1, FREM2, FUCA1, G6PC, G6PC3, GAA, GALC, GALE, GALK1, GALNS, GALNT3, GALT, GAMT, GATM, GBA, GBE1, GCDH, GCH1, GDF5, GFM1, GHR, GJB2, GJB6, GLB1, GLDC, GLE1, GNE, GNPAT, GNPTAB, GNPTG, GNS, GORAB, GRHRP, GRIP1, GSS, GUCY2D, GUSB, HADH, HADHA, HADHB, HAMP, HAX1, HBA1, HBA2, HBB, HEXA, HEXB, HGSNAT, HJV, HLCS, HMGCL, HMOX1, HOGA1, HPD, HPS1, HPS3, HPS4, HPS5, HPS6, HSD17B3, HSD17B4, HSD3B2, HYAL1, HYLS1, IDUA, IGHMBP2, IKBKB, IL7R, INVS, ITGA6, ITGB3, ITGB4, IVD, JAK3, KCNJ1, KCNJ11, LAMA2, LAMA3, LAMB3, LAMC2, LARGE1, LCA5, LDLR, LDLRAP1, LHX3, LIFR, LIG4, LIPA, LMBRD1, LOXHD1, LPL, LRAT, LRP2, LRP3, LRP4, LRP5, LRP6, LRP7, LRP8, LRP9, LRP10, LRP11, LRP12, LRP13, LRP14, LRP15, LRP16, LRP17, LRP18, LRP19, LRP20, LRP21, LRP22, LRP23, LRP24, LRP25, LRP26, LRP27, LRP28, LRP29, LRP30, LRP31, LRP32, LRP33, LRP34, LRP35, LRP36, LRP37, LRP38, LRP39, LRP40, LRP41, LRP42, LRP43, LRP44, LRP45, LRP46, LRP47, LRP48, LRP49, LRP50, LRP51, LRP52, LRP53, LRP54, LRP55, LRP56, LRP57, LRP58, LRP59, LRP60, LRP61, LRP62, LRP63, LRP64, LRP65, LRP66, LRP67, LRP68, LRP69, LRP70, LRP71, LRP72, LRP73, LRP74, LRP75, LRP76, LRP77, LRP78, LRP79, LRP80, LRP81, LRP82, LRP83, LRP84, LRP85, LRP86, LRP87, LRP88, LRP89, LRP90, LRP91, LRP92, LRP93, LRP94, LRP95, LRP96, LRP97, LRP98, LRP99, LRP100, LRP101, LRP102, LRP103, LRP104, LRP105, LRP106, LRP107, LRP108, LRP109, LRP110, LRP111, LRP112, LRP113, LRP114, LRP115, LRP116, LRP117, LRP118, LRP119, LRP120, LRP121, LRP122, LRP123, LRP124, LRP125, LRP126, LRP127, LRP128, LRP129, LRP130, LRP131, LRP132, LRP133, LRP134, LRP135, LRP136, LRP137, LRP138, LRP139, LRP140, LRP141, LRP142, LRP143, LRP144, LRP145, LRP146, LRP147, LRP148, LRP149, LRP150, LRP151, LRP152, LRP153, LRP154, LRP155, LRP156, LRP157, LRP158, LRP159, LRP160, LRP161, LRP162, LRP163, LRP164, LRP165, LRP166, LRP167, LRP168, LRP169, LRP170, LRP171, LRP172, LRP173, LRP174, LRP175, LRP176, LRP177, LRP178, LRP179, LRP180, LRP181, LRP182, LRP183, LRP184, LRP185, LRP186, LRP187, LRP188, LRP189, LRP190, LRP191, LRP192, LRP193, LRP194, LRP195, LRP196, LRP197, LRP198, LRP199, LRP200, LRP201, LRP202, LRP203, LRP204, LRP205, LRP206, LRP207, LRP208, LRP209, LRP210, LRP211, LRP212, LRP213, LRP214, LRP215, LRP216, LRP217, LRP218, LRP219, LRP220, LRP221, LRP222, LRP223, LRP224, LRP225, LRP226, LRP227, LRP228, LRP229, LRP230, LRP231, LRP232, LRP233, LRP234, LRP235, LRP236, LRP237, LRP238, LRP239, LRP240, LRP241, LRP242, LRP243, LRP244, LRP245, LRP246, LRP247, LRP248, LRP249, LRP250, LRP251, LRP252, LRP253, LRP254, LRP255, LRP256, LRP257, LRP258, LRP259, LRP260, LRP261, LRP262, LRP263, LRP264, LRP265, LRP266, LRP267, LRP268, LRP269, LRP270, LRP271, LRP272, LRP273, LRP274, LRP275, LRP276, LRP277, LRP278, LRP279, LRP280, LRP281, LRP282, LRP283, LRP284, LRP285, LRP286, LRP287, LRP288, LRP289, LRP290, LRP291, LRP292, LRP293, LRP294, LRP295, LRP296, LRP297, LRP298, LRP299, LRP300, LRP301, LRP302, LRP303, LRP304, LRP305, LRP306, LRP307, LRP308, LRP309, LRP310, LRP311, LRP312, LRP313, LRP314, LRP315, LRP316, LRP317, LRP318, LRP319, LRP320, LRP321, LRP322, LRP323, LRP324, LRP325, LRP326, LRP327, LRP328, LRP329, LRP330, LRP331, LRP332, LRP333, LRP334, LRP335, LRP336, LRP337, LRP338, LRP339, LRP340, LRP341, LRP342, LRP343, LRP344, LRP345, LRP346, LRP347, LRP348, LRP349, LRP350, LRP351, LRP352, LRP353, LRP354, LRP355, LRP356, LRP357, LRP358, LRP359, LRP360, LRP361, LRP362, LRP363, LRP364, LRP365, LRP366, LRP367, LRP368, LRP369, LRP370, LRP371, LRP372, LRP373, LRP374, LRP375, LRP376, LRP377, LRP378, LRP379, LRP380, LRP381, LRP382, LRP383, LRP384, LRP385, LRP386, LRP387, LRP388, LRP389, LRP390, LRP391, LRP392, LRP393, LRP394, LRP395, LRP396, LRP397, LRP398, LRP399, LRP400, LRP401, LRP402, LRP403, LRP404, LRP405, LRP406, LRP407, LRP408, LRP409, LRP410, LRP411, LRP412, LRP413, LRP414, LRP415, LRP416, LRP417, LRP418, LRP419, LRP420, LRP421, LRP422, LRP423, LRP424, LRP425, LRP426, LRP427, LRP428, LRP429, LRP430, LRP431, LRP432, LRP433, LRP434, LRP435, LRP436, LRP437, LRP438, LRP439, LRP440, LRP441, LRP442, LRP443, LRP444, LRP445, LRP446, LRP447, LRP448, LRP449, LRP450, LRP451, LRP452, LRP453, LRP454, LRP455, LRP456, LRP457, LRP458, LRP459, LRP460, LRP461, LRP462, LRP463, LRP464, LRP465, LRP466, LRP467, LRP468, LRP469, LRP470, LRP471, LRP472, LRP473, LRP474, LRP475, LRP476, LRP477, LRP478, LRP479, LRP480, LRP481, LRP482, LRP483, LRP484, LRP485, LRP486, LRP487, LRP488, LRP489, LRP490, LRP491, LRP492, LRP493, LRP494, LRP495, LRP496, LRP497, LRP498, LRP499, LRP500, LRP501, LRP502, LRP503, LRP504, LRP505, LRP506, LRP507, LRP508, LRP509, LRP510, LRP511, LRP512, LRP513, LRP514, LRP515, LRP516, LRP517, LRP518, LRP519, LRP520, LRP521, LRP522, LRP523, LRP524, LRP525, LRP526, LRP527, LRP528, LRP529, LRP530, LRP531, LRP532, LRP533, LRP534, LRP535, LRP536, LRP537, LRP538, LRP539, LRP540, LRP541, LRP542, LRP543, LRP544, LRP545, LRP546, LRP547, LRP548, LRP549, LRP550, LRP551, LRP552, LRP553, LRP554, LRP555, LRP556, LRP557, LRP558, LRP559, LRP560, LRP561, LRP562, LRP563, LRP564, LRP565, LRP566, LRP567, LRP568, LRP569, LRP570, LRP571, LRP572, LRP573, LRP574, LRP575, LRP576, LRP577, LRP578, LRP579, LRP580, LRP581, LRP582, LRP583, LRP584, LRP585, LRP586, LRP587, LRP588, LRP589, LRP590, LRP591, LRP592, LRP593, LRP594, LRP595, LRP596, LRP597, LRP598, LRP599, LRP600, LRP601, LRP602, LRP603, LRP604, LRP605, LRP606, LRP607, LRP608, LRP609, LRP610, LRP611, LRP612, LRP613, LRP614, LRP615, LRP616, LRP617, LRP618, LRP619, LRP620, LRP621, LRP622, LRP623, LRP624, LRP625, LRP626, LRP627, LRP628, LRP629, LRP630, LRP631, LRP632, LRP633, LRP634, LRP635, LRP636, LRP637, LRP638, LRP639, LRP640, LRP641, LRP642, LRP643, LRP644, LRP645, LRP646, LRP647, LRP648, LRP649, LRP650, LRP651, LRP652, LRP653, LRP654, LRP655, LRP656, LRP657, LRP658, LRP659, LRP660, LRP661, LRP662, LRP663, LRP664, LRP665, LRP666, LRP667, LRP668, LRP669, LRP670, LRP671, LRP672, LRP673, LRP674, LRP675, LRP676, LRP677, LRP678, LRP679, LRP680, LRP681, LRP682, LRP683, LRP684, LRP685, LRP686, LRP687, LRP688, LRP689, LRP690, LRP691, LRP692, LRP693, LRP694, LRP695, LRP696, LRP697, LRP698, LRP699, LRP700, LRP701, LRP702, LRP703, LRP704, LRP705, LRP706, LRP707, LRP708, LRP709, LRP710, LRP711, LRP712, LRP713, LRP714, LRP715, LRP716, LRP717, LRP718, LRP719, LRP720, LRP721, LRP722, LRP723, LRP724, LRP725, LRP726, LRP727, LRP728, LRP729, LRP730, LRP731, LRP732, LRP733, LRP734, LRP735, LRP736, LRP737, LRP738, LRP739, LRP740, LRP741, LRP742, LRP743, LRP744, LRP745, LRP746, LRP747, LRP748, LRP749, LRP750, LRP751, LRP752, LRP753, LRP754, LRP755, LRP756, LRP757, LRP758, LRP759, LRP760, LRP761, LRP762, LRP763, LRP764, LRP765, LRP766, LRP767, LRP768, LRP769, LRP770, LRP771, LRP772, LRP773, LRP774, LRP775, LRP776, LRP777, LRP778, LRP779, LRP780, LRP781, LRP782, LRP783, LRP784, LRP785, LRP786, LRP787, LRP788, LRP789, LRP790, LRP791, LRP792, LRP793, LRP794, LRP795, LRP796, LRP797, LRP798, LRP799, LRP800, LRP801, LRP802, LRP803, LRP804, LRP805, LRP806, LRP807, LRP808, LRP809, LRP810, LRP811, LRP812, LRP813, LRP814, LRP815, LRP816, LRP817, LRP818, LRP819, LRP820, LRP821, LRP822, LRP823, LRP824, LRP825, LRP826, LRP827, LRP828, LRP829, LRP830, LRP831, LRP832, LRP833, LRP834, LRP835, LRP836, LRP837, LRP838, LRP839, LRP840, LRP841, LRP842, LRP843, LRP844, LRP845, LRP846, LRP847, LRP848, LRP849, LRP850, LRP851, LRP852, LRP853, LRP854, LRP855, LRP856, LRP857, LRP858, LRP859, LRP860, LRP861, LRP862, LRP863, LRP864, LRP865, LRP866, LRP867, LRP868, LRP869, LRP870, LRP871, LRP872, LRP873, LRP874, LRP875, LRP876, LRP877, LRP878, LRP879, LRP880, LRP881, LRP882, LRP883, LRP884, LRP885, LRP886, LRP887, LRP888, LRP889, LRP890, LRP891, LRP892, LRP893, LRP894, LRP895, LRP896, LRP897, LRP898, LRP899, LRP900, LRP901, LRP902, LRP903, LRP904, LRP905, LRP906, LRP907, LRP908, LRP909, LRP910, LRP911, LRP912, LRP913, LRP914, LRP915, LRP916, LRP917, LRP918, LRP919, LRP920, LRP921, LRP922, LRP923, LRP924, LRP925, LRP926, LRP927, LRP928, LRP929, LRP930, LRP931, LRP932, LRP933, LRP934, LRP935, LRP936, LRP937, LRP938, LRP939, LRP940, LRP941, LRP942, LRP943, LRP944, LRP945, LRP946, LRP947, LRP948, LRP949, LRP950, LRP951, LRP952, LRP953, LRP954, LRP955, LRP956, LRP957, LRP958, LRP959, LRP960, LRP961, LRP962, LRP963, LRP964, LRP965, LRP966, LRP967, LRP968, LRP969, LRP970, LRP971, LRP972, LRP973, LRP974, LRP975, LRP976, LRP977, LRP978, LRP979, LRP980, LRP981, LRP982, LRP983, LRP984, LRP985, LRP986, LRP987, LRP988, LRP989, LRP990, LRP991, LRP992, LRP993, LRP994, LRP995, LRP996, LRP997, LRP998, LRP999, LRP1000, LRP1001, LRP1002, LRP1003, LRP1004, LRP1005, LRP1006, LRP1007, LRP1008, LRP1009, LRP1010, LRP1011, LRP1012, LRP1013, LRP1014, LRP1015, LRP1016, LRP1017, LRP1018, LRP1019, LRP1020, LRP1021, LRP1022, LRP1023, LRP1024, LRP1025, LRP1026, LRP1027, LRP1028, LRP1029, LRP1030, LRP1031, LRP1032, LRP1033, LRP1034, LRP1035, LRP1036, LRP1037, LRP1038, LRP1039, LRP1040, LRP1041, LRP1042, LRP1043, LRP1044, LRP1045, LRP1046, LRP1047, LRP1048, LRP1049, LRP1050, LRP1051, LRP1052, LRP1053, LRP1054, LRP1055, LRP1056, LRP1057, LRP1058, LRP1059, LRP1060, LRP1061, LRP1062, LRP1063, LRP1064, LRP1065, LRP1066, LRP1067, LRP1068, LRP1069, LRP1070, LRP1071, LRP1072, LRP1073, LRP1074, LRP1075, LRP1076, LRP1077, LRP1078, LRP1079, LRP1080, LRP1081, LRP1082, LRP1083, LRP1084, LRP1085, LRP1086, LRP1087, LRP1088, LRP1089, LRP1090, LRP1091, LRP1092, LRP1093, LRP1094, LRP1095, LRP1096, LRP1097, LRP1098, LRP1099, LRP1100, LRP1101, LRP1102, LRP1103, LRP1104, LRP1105, LRP1106, LRP1107, LRP1108, LRP1109, LRP1110, LRP1111, LRP1112, LRP1113, LRP1114, LRP1115, LRP1116, LRP1117, LRP1118, LRP1119, LRP1120, LRP1121, LRP1122, LRP1123, LRP1124, LRP1125, LRP1126, LRP1127, LRP1128, LRP1129, LRP1130, LRP1131, LRP1132, LRP1133, LRP1134, LRP1135, LRP1136, LRP1137, LRP1138, LRP1139, LRP1140, LRP1141, LRP1142, LRP1143, LRP1144, LRP1145, LRP1146, LRP1147, LRP1148, LRP1149, LRP1150, LRP1151, LRP1152, LRP1153, LRP1154, LRP1155, LRP1156, LRP1157, LRP1158, LRP1159, LRP1160, LRP1161, LRP1162, LRP1163, LRP1164, LRP1165, LRP1166, LRP1167, LRP1168, LRP1169, LRP1170, LRP1171, LRP1172, LRP1173, LRP1174, LRP1175, LRP1176, LRP1177, LRP1178, LRP1179, LRP1180, LRP1181, LRP1182, LRP1183, LRP1184, LRP1185, LRP1186, LRP1187, LRP1188, LRP1189, LRP1190, LRP1191, LRP1192, LRP1193, LRP1194, LRP1195, LRP1196, LRP1197, LRP1198, LRP1199, LRP1200, LRP1201, LRP1202, LRP1203, LRP1204, LRP1205, LRP1206, LRP1207, LRP1208, LRP1209, LRP1210, LRP1211, LRP1212, LRP1213, LRP1214, LRP1215, LRP1216, LRP1217, LRP1218, LRP1219, LRP1220, LRP1221, LRP1222, LRP1223, LRP1224, LRP1225, LRP1226, LRP1227, LRP1228, LRP1229, LRP1230, LRP1231, LRP1232, LRP1233, LRP1234, LRP1235, LRP1236, LRP1237, LRP1238, LRP1239, LRP1240, LRP1241, LRP1242, LRP1243, LRP1244, LRP1245, LRP1246, LRP1247, LRP1248, LRP1249, LRP1250, LRP1251, LRP1252, LRP1253, LRP1254, LRP1255, LRP1256, LRP1257, LRP1258, LRP1259, LRP1260, LRP1261, LRP1262, LRP1263, LRP1264, LRP1265, LRP1266, LRP1267, LRP1268, LRP1269, LRP1270, LRP1271, LRP1272, LRP1273, LRP1274, LRP1275, LRP1276, LRP1277, LRP1278, LRP1279, LRP1280, LRP1281, LRP1282, LRP1283, LRP1284, LRP1285, LRP1286, LRP1287, LRP1288, LRP1289, LRP1290, LRP1291, LRP1292, LRP1293, LRP1294, LRP1295, LRP1296, LRP1297, LRP1298, LRP1299, LRP1300, LRP1301, LRP1302, LRP1303, LRP1304, LRP1305, LRP1306, LRP1307, LRP1308, LRP1309, LRP1310, LRP1311, LRP1312, LRP1313, LRP1314, LRP1315, LRP1316, LRP1317, LRP1318, LRP1319, LRP1320, LRP1321, LRP1322, LRP1323, LRP1324, LRP1325, LRP1326, LRP1327, LRP1328, LRP1329, LRP1330, LRP1331, LRP1332, LRP1333, LRP1334, LRP1335, LRP1336, LRP1337, LRP1338, LRP1339, LRP1340, LRP1341, LRP1342, LRP1343, LRP1344, LRP1345, LRP1346, LRP1347, LRP1348, LRP1349, LRP1350, LRP1351, LRP1352, LRP1353, LRP1354, LRP1355, LRP1356, LRP1357, LRP1358, LRP1359, LRP1360, LRP1361, LRP1362, LRP1363, LRP1364, LRP1365, LRP1366, LRP1367, LRP1368, LRP1369, LRP1370, LRP1371, LRP1372, LRP1373, LRP1374, LRP1375, LRP1376, LRP1377, LRP1378, LRP1379, LRP1380, LRP1381, LRP1382, LRP1383, LRP1384, LRP1385, LRP1386, LRP1387, LRP1388, LRP1389, LRP1390, LRP1391, LRP1392, LRP1393, LRP1394, LRP1395, LRP1396, LRP1397, LRP1398, LRP1399, LRP1400, LRP1401, LRP1402, LRP1403, LRP1404, LRP1405, LRP1406, LRP1407, LRP1408, LRP1409, LRP1410, LRP1411, LRP1412, LRP1413, LRP1414, LRP1415, LRP1416, LRP1417, LRP1418, LRP1419, LRP1420, LRP1421, LRP1422, LRP1423, LRP1424, LRP1425, LRP1426, LRP1427, LRP1428, LRP1429, LRP1430, LRP1431, LRP1432, LRP1433, LRP1434, LRP1435, LRP1436, LRP1437, LRP1438, LRP1439, LRP1440, LRP1441, LRP1442, LRP1443, LRP1444, LRP1445, LRP1446, LRP1447, LRP1448, LRP1449, LRP1450, LRP1451, LRP1452, LRP1453, LRP1454, LRP1455, LRP1456, LRP1457, LRP1458, LRP1459, LRP1460, LRP1461, LRP1462, LRP1463, LRP1464, LRP1465, LRP1466, LRP1467, LRP1468, LRP1469, LRP1470, LRP1471, LRP1472, LRP1473, LRP1474, LRP1475, LRP1476, LRP1477, LRP1478, LRP1479, LRP1480, LRP1481, LRP1482, LRP1483, LRP1484, LRP1485, LRP1486, LRP1487, LRP1488, LRP1489, LRP1490, LRP1491, LRP1492, LRP1493, LRP1494, LRP1495, LRP1496, LRP1497, LRP1498, LRP1499, LRP1500, LRP1501, LRP1502, LRP1503, LRP1504, LRP1505, LRP1506, LRP1507, LRP1508, LRP1509, LRP1510, LRP1511, LRP1512, LRP1513, LRP1514, LRP1515, LRP1516, LRP1517, LRP1518, LRP1519, LRP1520, LRP1521, LRP1522, LRP1523, LRP1524, LRP1525, LRP1526, LRP1527, LRP1528, LRP1529, LRP1530, LRP1531, LRP1532, LRP1533, LRP1534, LRP1535, LRP1536, LRP1537, LRP1538, LRP1539, LRP1540, LRP1541, LRP1542, LRP1543, LRP1544, LRP1545, LRP1546, LRP1547, LRP1548, LRP1549, LRP1550, LRP1551, LRP1552, LRP1553, LRP1554, LRP1555, LRP1556, LRP1557, LRP1558, LRP1559, LRP1560, LRP1561, LRP1562, LRP1563, LRP1564, LRP1565, LRP1566, LRP1567, LRP1568, LRP1569, LRP1570, LRP1571, LRP1572, LRP1573, LRP1574, LRP1575, LRP1576, LRP1577, LRP1578, LRP1579, LRP1580, LRP1581, LRP1582, LRP1583, LRP1584, LRP1585, LRP1586, LRP1587, LRP1588, LRP1589, LRP1590, LRP1591, LRP1592, LRP1593, LRP1594, LRP1595, LRP1596, LRP1597, LRP1598, LRP1599, LRP1600, LRP1601, LRP1602, LRP1603, LRP1604, LRP1605, LRP1606, LRP1607, LRP1608, LRP1609, LRP1610, LRP1611, LRP1612, LRP1613, LRP1614, LRP1615, LRP1616, LRP1617, LRP1618, LRP1619, LRP1620, LRP1621, LRP1622, LRP1623, LRP1624, LRP1625, LRP1626, LRP1627, LRP1628, LRP1629, LRP1630, LRP1631, LRP1632, LRP1633, LRP1634, LRP1635, LRP1636, LRP1637, LRP1638, LRP1639, LRP1640, LRP1641, LRP1642, LRP1643, LRP1644, LRP1645, LRP1646, LRP1647, LRP1648, LRP1649, LRP1650, LRP1651, LRP1652, LRP1653, LRP1654, LRP1655, LRP1656, LRP1657, LRP1658, LRP1659, LRP1660, LRP1661, LRP1662, LRP1663, LRP1664, LRP1665, LRP1666, LRP1667, LRP1668, LRP1669, LRP1670, LRP1671, LRP1672, LRP1673, LRP1674, LRP1675, LRP1676, LRP1677, LRP1678, LRP1679, LRP1680, LRP1681, LRP1682, LRP1683, LRP16



otherwise, to future pregnancies, and negative results do not rule out the genetic risk to a pregnancy. Official gene names change over time. Fulgent uses the most up to date gene names based on HUGO Gene Nomenclature Committee (<https://www.genenames.org>) recommendations. If the gene name on report does not match that of ordered gene, please contact the laboratory and details can be provided. Result interpretation is based on the available clinical and family history information for this individual, collected published information, and Alamut annotation available at the time of reporting. This assay is not designed or validated for the detection of low-level mosaicism or somatic mutations. This assay will not detect certain types of genomic aberrations such as translocations, inversions, or repeat expansions other than specified genes. DNA alterations in regulatory regions or deep intronic regions (greater than 20bp from an exon) may not be detected by this test. Unless otherwise indicated, no additional assays have been performed to evaluate genetic changes in this specimen. There are technical limitations on the ability of DNA sequencing to detect small insertions and deletions. Our laboratory uses a sensitive detection algorithm, however these types of alterations are not detected as reliably as single nucleotide variants. Rarely, due to systematic chemical, computational, or human error, DNA variants may be missed. Although next generation sequencing technologies and our bioinformatics analysis significantly reduce the confounding contribution of pseudogene sequences or other highly-homologous sequences, sometimes these may still interfere with the technical ability of the assay to identify pathogenic alterations in both sequencing and deletion/duplication analyses. Deletion/duplication analysis can identify alterations of genomic regions which include one whole gene (buccal swab specimens and whole blood specimens) and are two or more contiguous exons in size (whole blood specimens only); single exon deletions or duplications may occasionally be identified, but are not routinely detected by this test. When novel DNA duplications are identified, it is not possible to discern the genomic location or orientation of the duplicated segment, hence the effect of the duplication cannot be predicted. Where deletions are detected, it is not always possible to determine whether the predicted product will remain in-frame or not. Unless otherwise indicated, deletion/duplication analysis has not been performed in regions that have been sequenced by Sanger.

Gene Specific Notes and Limitations

ALG1: Due to the interference by highly homologous regions, our current testing method has less sensitivity to detect variants in exons 6-13 of the ALG1 gene (NM_019109.4). CEP290: Copy number analysis for exons 8-13 and exons 39-42 may have reduced sensitivity in the CEP290 gene. Confirmation of these exons are limited to individuals with a positive personal history of CEP290-related conditions and/or individuals carrying a pathogenic/likely pathogenic sequence variant. CFTR: Analysis of the intron 8 polymorphic region (e.g. IVS8-5T allele) is only performed if the p.Arg117His (R117H) mutation is detected. Single exon deletion/duplication analysis is limited to deletions of previously reported exons: 1, 2, 3, 11, 19, 20, 21. Analysis of the intron 8 polymorphic region (e.g. IVS8-5T allele) is only performed if the p.Arg117His (R117H) mutation is detected. Single exon deletion/duplication analysis is limited to deletions of previously reported exons: 1, 2, 3, 11, 19, 20, 21. CFTR variants primarily associated with CFTR-related isolated congenital bilateral absence of the vas deferens and CFTR-related pancreatitis are not included in this analysis. CFTR variants with insufficient evidence of being cystic fibrosis mutations will not be reported either. CRYL1: As mutations in the CRYL1 gene are not known to be associated with any clinical condition, sequence variants in this gene are not analyzed. However, to increase copy number detection sensitivity for large deletions including this gene and a neighboring gene on the panel (GJB6, also known as connexin 30), this gene was evaluated for copy number variation. CYP11B1: The current testing method is not able to reliably detect certain pathogenic variants in this gene due to the interference by highly homologous regions. This analysis is not designed to detect or rule-out copy-neutral chimeric CYP11B1/CYP11B2 gene. CYP11B2: The current testing method is not able to reliably detect certain pathogenic variants in this gene due to the interference by highly homologous regions. This analysis is not designed to detect or rule-out copy-neutral chimeric CYP11B1/CYP11B2 gene. CYP21A2: Significant pseudogene interference and/or reciprocal exchanges between the CYP21A2 gene and its pseudogene, CYP21A1P, have been known to occur and may impact results. As such, the relevance of variants reported in this gene must be interpreted clinically in the context of the clinical findings, biochemical profile, and family history of each patient. LR-PCR is not routinely ordered for NM_000500.9:c.955C>T (p.Gln319Ter). Individuals with c.955C>T (p.Gln319Ter) will be reported as a Possible Carrier indicating that the precise nature of the variant has not been determined by LR-PCR and that the variant may occur in the CYP21A2 wild-type gene or in the CYP21A1P pseudogene. The confirmation test is recommended if the second reproductive partner is tested positive for variants associated with classic CAH. DDX11: Due to the interference by highly homologous regions, our current testing method has less sensitivity to detect variants in the DDX11 gene. DUOX2: The current testing method is not able to reliably detect variants in exons 6-8 of the DUOX2 gene (NM_014080.5) due to significant interference by the highly homologous gene, DUOX1. FANCD2: Due to pseudogene interference, copy-number-variants within exon 14-17 of the FANCD2 gene (NM_033084.4) are not evaluated and detection of single-nucleotide variants and small insertions/deletions in this region is not guaranteed. GALT: In general, the D2 "Duarte" allele is not reported if detected, but can be reported upon request. While this allele can cause positive newborn screening results, it is not known to cause clinical symptoms in any state. See GeneReviews for more information: <https://www.ncbi.nlm.nih.gov/books/NBK1518/> GBA: Significant pseudogene interference and/or reciprocal exchanges between the GBA gene and its pseudogene, GBAP1, have been known to occur and may impact results. As such, the relevance of variants reported in this gene must be interpreted clinically in the context of this individual's clinical findings, biochemical profile, and family history. The current testing method cannot detect copy-neutral rearrangements between the pseudogene and the functional gene, which have been reported in very rare cases of Gaucher disease (PubMed: 21704274). HBA1: Significant interference



from highly homologous regions in exons 1-2 of the HBA1 gene has been recognized to occur, potentially impeding the assay's technical capability to detect pathogenic alterations during sequencing analyses. **HBA2:** Significant interference from highly homologous regions in exons 1-2 of the HBA2 gene has been recognized to occur, potentially impeding the assay's technical capability to detect pathogenic alterations during sequencing analyses. **HSD17B4:** Copy number analysis for exons 4-6 may have reduced sensitivity in the HSD17B4 gene. Confirmation of these exons are limited to individuals with a positive personal history of D-bifunctional protein deficiency and Perrault syndrome and/or individuals carrying a pathogenic/likely pathogenic sequence variant. **LMBRD1:** Copy number analysis for exons 9-12 may have reduced sensitivity in the LMBRD1 gene. Confirmation of these exons are limited to individuals with a positive personal history of combined methylmalonic aciduria and homocystinuria and/or individuals carrying a pathogenic/likely pathogenic sequence variant. **MTHFR:** As recommended by ACMG, the two common polymorphisms in the MTHFR gene - c.1286A>C (p.Glu429Ala, also known as c.1298A>C) and c.665C>T (p.Ala222Val, also known as c.677C>T) - are not reported in this test due to lack of sufficient clinical utility to merit testing (PubMed: [23288205](#)). **NEB:** This gene contains a 32-kb triplicate region (exons 82-105) which is not amenable to sequencing and deletion/duplication analysis. **NPHS2:** If detected, the variant NM_014625.3:c.686G>A (p.Arg229Gln) will not be reported as this variant is not significantly associated with disease when homozygous or in the compound heterozygous state with variants in exons 1-6 of NPHS2. **OTOA:** Due to pseudogene interference, our current testing method is not able to reliably detect variants in exons 20-28 (NM_144672.3) in the OTOA gene. **SMN1:** The current testing method detects sequencing variants in exon 7 and copy number variations in exons 7-8 of the SMN1 gene (NM_022874.2). Sequencing and deletion/duplication analysis are not performed on any other region in this gene. About 5%-8% of the population have two copies of SMN1 on a single chromosome and a deletion on the other chromosome, known as a [2+0] configuration (PubMed: [20301526](#)). The current testing method cannot directly detect carriers with a [2+0] SMN1 configuration but can detect linkage between the silent carrier allele and certain population-specific single nucleotide changes. As a result, a negative result for carrier testing greatly reduces but does not eliminate the chance that a person is a carrier. Only abnormal results will be reported. **TERT:** The TERT promoter region is analyzed for both sequencing and copy number variants. **TYR:** Due to the interference by highly homologous regions, our current testing method has less sensitivity to detect variants in exons 4-5 of the TYR gene (NM_000372.5). **VPS45:** LoF is not a known disease mechanism. **WRN:** Due to the interference by highly homologous regions within the WRN gene, our current testing method has less sensitivity to detect variants in exons 10-11 of WRN (NM_000553.6).

SIGNATURE:



Geetu Mendiratta-Vij, PhD, FACMG, CGMBS on 4/26/2024
Laboratory Director, Fulgent

DISCLAIMER:

This test was developed and its performance characteristics determined by Fulgent Therapeutics LLC CAP #8042697 CLIA #05D2043189; 4399 Santa Anita Ave., El Monte, CA, 91731. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. Since genetic variation, as well as systematic and technical factors, can affect the accuracy of testing, the results of testing should always be interpreted in the context of clinical and familial data. For assistance with interpretation of these results, healthcare professionals may contact us directly at [626-350-0537](tel:626-350-0537) or by email at info@fulgentgenetics.com. It is recommended that patients receive appropriate genetic counseling to explain the implications of the test result, including its residual risks, uncertainties and reproductive or medical options.

To view the supplemental table describing the carrier frequencies, detection rates, and residual risks associated with the genes on this test please visit the following link:

[Beacon Expanded Carrier Screening Supplemental Table](#)





Patient Information	Specimen Information	Client Information
13156, DONOR DOB: ████████ AGE: ██████ Gender: M Fasting: U Phone: 206.588.1484 Patient ID: 13156 Health ID: 8573034372838457	Specimen: OW046793A Requisition: 0000639 Collected: 04/10/2024 / 10:15 PDT Received: 04/11/2024 / 04:45 PDT Reported: 04/22/2024 / 22:22 PDT	Client #: 98105026 VNLZR00 KUAN, JAMES K SEATTLE SPERM BANK 4915 25TH AVE NE STE 204W SEATTLE, WA 98105-5668

COMMENTS: FASTING:UNKNOWN

Cytogenetic Report

CHROMOSOME ANALYSIS, BLOOD - 14596 **Lab: EZ**

CHROMOSOME ANALYSIS, BLOOD

Order ID: 24-171082
 Specimen Type: Blood
 Clinical Indication: Rule out chromosome abnormality

RESULT:
 NORMAL MALE KARYOTYPE

INTERPRETATION:
 Chromosome analysis revealed normal G-band patterns within the limits of standard cytogenetic analysis.

Please expect the results of any other concurrent study in a separate report.

NOMENCLATURE:
 46,XY

ASSAY INFORMATION:

Method: G-Band (Digital Analysis: MetaSyst)
 Cells Counted: 20
 Band Level: 450
 Cells Analyzed: 5
 Cells Karyotyped: 5


This test does not address genetic disorders that cannot be detected by standard cytogenetic methods or rare events such as low level mosaicism or subtle rearrangements.

Reha M. Toydemir, MD, PhD, FACMG, [site SJC5]

Electronic Signature: 4/23/2024 12:40 AM



Patient Information	Specimen Information	Client Information
13156, DONOR DOB: ██████████ AGE: ██████ Gender: M Fasting: U Patient ID: 13156 Health ID: 8573034372838457	Specimen: OW046793A Collected: 04/10/2024 / 10:15 PDT Received: 04/11/2024 / 04:45 PDT Reported: 04/22/2024 / 22:22 PDT	Client #: 98105026 KUAN, JAMES K



PERFORMING SITE:

EZ QUEST DIAGNOSTICS/NICHOLS SJ, 33608 ORTEGA HWY, SAN JUAN CAPISTRANO, CA 92675-2042 Laboratory Director: IRINA MARAMICA,MD,PHD,MBA, CLIA: 05D0643352